Status:
COMPLETED
Isoniazid Prophylaxis Based on Risk Factors of Tuberculosis in Living Kidney Transplantation Recipients
Lead Sponsor:
West China Hospital
Conditions:
Kidney Transplantation
Tuberculosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Tuberculosis (TB) is a major and severe opportunistic infection among solid organ transplant recipients. Chemoprophylaxis is advised for those with latent tuberculosis infection (LTBI). However, the e...
Eligibility Criteria
Inclusion
- living-donor kidney transplant recipients
- receiving standard triad immunosuppressive regimen
Exclusion
- active TB infection
- multiorgan transplantation
- liver cirrhosis
- malignancy history in the donor and recipient
- human immunodeficiency virus infection
- those who had received a nine-month course of INH.
Key Trial Info
Start Date :
June 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2024
Estimated Enrollment :
1348 Patients enrolled
Trial Details
Trial ID
NCT06512831
Start Date
June 1 2023
End Date
March 1 2024
Last Update
July 22 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
West China Hospital, Sichuan University
Chengdu, Sichuan, China, 610041